RemeGen Co., Ltd.*

榮昌生物製藥(煙台)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 9995)

ANNOUNCEMENT ON INCREASE OF REGISTERED CAPITAL OF THE COMPANY AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION

This announcement is made by RemeGen Co., Ltd.* (the "**Company**") pursuant to Rule 13.51(1) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

References are made to the announcements of the Company dated May 10, 2021, June 21, 2021, November 8, 2021, November 11, 2021, November 28, 2022, January 12, 2022, February 20, 2022, March 14, 2022, March 21, 2022 and March 30, 2022 and circulars dated May 14, 2021 and December 2, 2021, which include, among other things, matters related to the A share offering by the Company (the "**A Share Offering**"). Unless the context requires otherwise, terms and expressions used in this announcement shall have the same meanings as those defined in the aforementioned announcements and circulars.

As approved by China Securities Regulatory Commission in the "Approval of Registration in relation to the Initial Public Offering of Shares by RemeGen Co., Ltd." (Zheng Jian Xu Ke [2022] No. 62)", the Company has completed the A Share Offering and issued in aggregate 54,426,301 A Shares. The new shares issued under the A Share Offering have been registered and deposited in Shanghai Branch of China Securities Depository and Clearing Corporation Limited on March 28, 2022. The total number of shares of the Company increased from 489,836,702 to 544,263,003 and the registered capital of the Company has increased from RMB489,836,702 to RMB544,263,003.

In light of the above, according to the resolutions regarding proposed issue of A Shares and listing on the Sci-Tech Board and other ancillary resolutions, including, among others, authorization to the Board of Directors to fully handle the relevant matters in connection with the issue of A Shares and listing on the Sci-Tech Board considered and approved at the Company's 2021 second extraordinary general meeting, 2021 first class meeting of H shareholders and 2021 first class meeting of domestic shareholders and unlisted foreign shareholders on June 1, 2021, the articles related to the registered capital and the total number of shares of the Company in the articles of association of the Company (the "**Articles of Association**") are amended. The amendments to the Articles of Association are as follows:

Comparison Chart of Amendments to the Articles of Association of RemeGen Co., Ltd.*

Original article	Amended as
Article 5 The registered capital of the Company is RMB[●] million.	**Article 5** The registered capital of the Company is RMB**544,263,003**.
Article 19 Upon completion of the initial public offering of overseas listed foreign shares, if the capital structure of the Company shall comprise of: 478,356,202 ordinary shares (before the Over-allotment Option is exercised), including 239,294,291 domestic shares, accounting for 50.02% of the total number of ordinary shares of the Company; 132,193,534 unlisted foreign shares, accounting for 27.64% of the total number of ordinary shares of the Company; and 106,868,377 H Shares, accounting for 22.34% of the total number of ordinary shares of the Company. If the Over-allotment Option is fully exercised, the capital structure of the Company shall comprise of: 489,836,702 ordinary shares, including 239,294,291 domestic shares, accounting for 48.85% of the total number of ordinary shares of the Company; 132,193,534 unlisted foreign shares, accounting for 26.99% of the total number of ordinary shares of the Company; and 118,348,877 H Shares, accounting for 24.16% of the total number of ordinary shares of the Company.	**Article 19** Upon completion of the initial public offering of overseas listed foreign shares, if the capital structure of the Company shall comprise of: 478,356,202 ordinary shares (before the Over-allotment Option is exercised), including 239,294,291 domestic shares, accounting for 50.02% of the total number of ordinary shares of the Company; 132,193,534 unlisted foreign shares, accounting for 27.64% of the total number of ordinary shares of the Company; and 106,868,377 H Shares, accounting for 22.34% of the total number of ordinary shares of the Company. If the Over-allotment Option is fully exercised, the capital structure of the Company shall comprise of: 489,836,702 ordinary shares, including 239,294,291 domestic shares, accounting for 48.85% of the total number of ordinary shares of the Company; 132,193,534 unlisted foreign shares, accounting for 26.99% of the total number of ordinary shares of the Company; and 118,348,877 H Shares, accounting for 24.16% of the total number of ordinary shares of the Company.

Original article	Amended as
With the approval of the China Securities Regulatory Commission ("CSRC"), 15 shareholders of the Company converted a total of 71,232,362 domestic unlisted shares into overseas listed foreign shares, and the relevant shares may be listed on the Hong Kong Stock Exchange upon completion of the conversion. With the consent of the Shanghai Stock Exchange ("SSE") and registration with the CSRC, the Company made an initial public offering of [●] domestic RMB ordinary shares (A shares), which was listed on the Science and Technology Innovation Board on [●]. After the completion of the conversion of the above-mentioned domestic unlisted shares into overseas listed foreign shares and the completion of the initial public offering and listing of domestic RMB ordinary shares (A shares), the share capital structure of the Company is as follows: [●] ordinary shares, of which: [●] domestic RMB ordinary shares (A shares), accounting for [●]% of the total number of ordinary shares of the Company; [●] H shares, accounting for [●]% of the total number of ordinary shares of the Company.	With the approval of the China Securities Regulatory Commission ("CSRC"), 15 shareholders of the Company converted a total of 71,232,362 domestic unlisted shares into overseas listed foreign shares, and the relevant shares may be listed on the Hong Kong Stock Exchange upon completion of the conversion. With the consent of the Shanghai Stock Exchange ("SSE") and registration with the CSRC, the Company made an initial public offering of **54,426,301** domestic RMB ordinary shares (A shares), which was listed on the Science and Technology Innovation Board on **March 31, 2022**. After the completion of the conversion of the above-mentioned domestic unlisted shares into overseas listed foreign shares and the completion of the initial public offering and listing of domestic RMB ordinary shares (A shares), the share capital structure of the Company is as follows: **544,263,003** ordinary shares, of which: **354,681,764** domestic RMB ordinary shares (A shares), accounting for **65.17**% of the total number of ordinary shares of the Company; **189,581,239** H shares, accounting for **34.83**% of the total number of ordinary shares of the Company.

For details of the amended Articles of Association, please refer to the websites of Shanghai Stock Exchange (http://www.sse.com.cn), the Hong Kong Stock Exchange (http://www.hkexnews.hk) and the Company (www.remegen.cn). The Company will complete the change of industry and commerce registration and the filing procedures according to the relevant requirements.

By order of the Board
RemeGen Co., Ltd.*
Mr. Wang Weidong
Chairman and executive director

Yantai, PRC
April 19, 2022

As at the date of this announcement, the Board comprises Mr. Wang Weidong, Dr. Fang Jianmin, Dr. He Ruyi and Mr. Lin Jian as the executive directors, Dr. Wang Liqiang and Dr. Su Xiaodi as the non-executive directors, and Ms. Yu Shanshan, Mr. Hao Xianjing and Dr. Ma Lan as the independent non-executive directors.

* *For identification purpose only*